Louis Lasagna

Q: What Schools Are Affiliated With Louis Lasagna

Louis Lasagna is affiliated with the following schools: Tufts University, Rutgers University, Johns Hopkins University, Massachusetts General Hospital, University of Rochester

Louis Lasagna's AcademicInfluence.com Rankings

Louis Lasagna

Medical

#38

World Rank

#72

Historical Rank

#21

USA Rank

Pharmacology

World Rank

#13

Historical Rank

USA Rank

medical Degrees

Louis Lasagna

Philosophy

#1886

World Rank

#3333

Historical Rank

#712

USA Rank

Logic

#537

World Rank

#978

Historical Rank

#213

USA Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Louis Lasagna Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Louis Cesare Lasagna was an American physician and professor of medicine, known for his revision of the Hippocratic Oath. Early life and education Lasagna was an internationally recognized and respected expert in clinical pharmacology. Born in Queens, New York in 1923, Lasagna was raised in New Brunswick, New Jersey, by his Italian immigrant parents, and graduated from New Brunswick High School. He graduated from Rutgers University in 1943 and earned his medical degree from Columbia University in 1947. During his time at Rutgers University, he joined Kappa Sigma Fraternity . After completing a clinical research fellowship in anesthesia at Harvard Medical School, Lasagna joined the faculty of Johns Hopkins University in 1954, where he established the first ever clinical pharmacology department. Lasagna taught medicine and pharmacology at Johns Hopkins until 1970, when he accepted the position as the first chairman of the Department of Pharmacology and Toxicology at the University of Rochester's, School of Medicine and Dentistry, which he held for the next decade . Early in his fourteen-year career at Rochester, Lasagna founded the Center for the Study of Drug Development, later called the Tufts Center for the Study of Drug Development. In July 1984, the Center moved with Lasagna to Tufts University, where he became dean of the Sackler School of Graduate Biomedical Sciences.

(See a Problem?)

Louis Lasagna's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide (1960) (1034)
Cost of innovation in the pharmaceutical industry. (1991) (718)
Adverse drug reactions. A critical review. (1975) (529)
Studies with different types of visual analog scales for measurement of pain (1983) (495)
Toward the operational identification of adverse drug reactions (1977) (460)
A study of the placebo response. (1954) (408)
Drug-induced mood changes in man. I. Observations on healthy subjects, chronically ill patients, and postaddicts. (1955) (263)
Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: A regulatory perspective (1995) (199)
The analgesic effectiveness of nalorphine and nalorphine-morphine combinations in man. (1954) (197)
Attitudes of patients, housestaff, and nurses toward postoperative analgesic care. (1983) (169)
Long‐term weight control study I (weeks 0 to 34) (1992) (168)
Analysis of Narcotic Analgesic Usage in the Treatment of Postoperative Pain (1983) (164)
Adverse drug reactions—a matter of opinion (1976) (143)
Compliance as a determinant of serum digoxin concentration. (1973) (139)
Effects of mode of management on plasma chlorpromazine in psychiatric patients (1973) (132)
The Relationship between Physician Characteristics and Prescribing Appropriateness (1972) (131)
Obtaining Informed Consent: Form or Substance (1969) (130)
Clinical response and plasma levels: effect of dose, dosage schedules, and drug interactions on plasma chlorpromazine levels. (1976) (128)
Drugs as etiologic factors in the Stevens-Johnson syndrome. (1968) (126)
Drug Interaction in the Field of Analgesic Drugs (1965) (124)
Do "placebo responders" exist? (2008) (123)
The effectiveness of oral analgesics (morphine, codeine, acetylsalicylic acid) and the problem of placebo "reactors" and "non-reactors". (1953) (118)
The optimal dose of morphine. (1954) (115)
Drug-induced mood changes in man. II. Personality and reactions to drugs. (1955) (114)
New drug development in the United States from 1963 to 1990 (1991) (113)
The effects of aggregation, electric shock, and adrenergic blocking drugs on inhibition of the "writhing syndrome". (1963) (112)
A study of cross‐tolerance to circulatory effects of organic nitrates (1967) (106)
Further studies on the pharmacology of placebo administration. (1958) (101)
The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin. (1956) (100)
Drug prescribing and use in an American community. (1972) (98)
Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: Issues of safety (1984) (97)
Attitudes of Patients, Housestaff, and Nurses Toward Postoperative Analgesic Care (1983) (95)
Effect of tranquilizing drugs on amphetamine toxicity in aggregated mice. (1957) (93)
The volunteer subject in research. (1954) (92)
New drug development in the United States from 1963 to 1992 (1994) (91)
L-dopa treatment failure: explanation and correction. (1970) (89)
THE CLINICAL EVALUATION OF MORPHINE AND ITS SUBSTITUTES AS ANALGESICS. (1964) (88)
Absorption and Metabolism of L‐Dopa by the Human Stomach (1971) (86)
Prescribing patterns of physicians. (1969) (85)
Variations in interpretation of prescription instructions. The need for improved prescribing habits. (1974) (84)
The controlled clinical trial: theory and practice. (1955) (84)
Relation of thyroid function to acute and chronic effects of amphetamine in the rat. (1960) (83)
THE CLINICAL MEASUREMENT OF PAIN (1960) (82)
Gustatory Thresholds in Patients with Hypertension (1962) (82)
Differential education concerning therapeutics and resultant physician prescribing patterns. (1972) (82)
The quantification of pain: An analysis of words used to describe pain and analgesia in clinical trials (1982) (81)
METABOLISM AND ABSORPTION OF l‐3,4 DIHYDROXYPHENYLALANINE IN PATIENTS WITH PARKINSON'S DISEASE (1971) (79)
Effect of cyproheptadine on asthmatic children. Study of appetite, weight gain, and linear growth. (1962) (77)
Analysis of narcotic analgesic usage in the treatment of postoperative pain. (1984) (73)
Methotrimeprazine: a new phenothiazine derivative with analgesic properties. (1961) (72)
The nature of evidence. (1972) (70)
New drug development in the United States, 1963 through 1984 (1988) (66)
A controlled trial of urethane treatment in multiple myeloma. (1966) (65)
Obtaining informed consent. Form or substance. (1970) (63)
Regulation and drug development (1975) (61)
ABNORMAL TASTE THRESHOLD IN DIABETES. (1965) (59)
Patient package inserts. I. Nature, notions, and needs (1975) (57)
Problems in publlcatlon of clinical trial methodology (1979) (57)
Experimental bases for the different hepatotoxicity of erythromycin preparations in man. (1972) (57)
THE ANALGESIC EFFICACY AND RESPIRATORY EFFECTS IN MAN OF A BENZOMORPHAN "NARCOTIC ANTAGONIST" (1964) (54)
A study of hypnotic drugs in patients with chronic diseases; comparative efficacy of placebo; methyprylon (noludar) meprobmate (miltown, equanil) pentobarbial; phenobarbital; secobarbital. (1956) (54)
The drug lag: An update of new drug introductions in the United States and in the United Kingdom, 1977 through 1987 (1989) (51)
Analgesic methodology: a brief history and commentary. (1980) (49)
Phenylpropanolamine: A review (1988) (48)
Analgesic potency of normorphine in patients with postoperative pain. (1958) (46)
The New Drug Approvals of 1990, 1991, and 1992: Trends in Drug Development (1994) (42)
Dose‐related sleep disturbances induced by coffee and caffeine (1977) (42)
Oral contraceptive patient information. A questionnaire study of attitudes, knowledge, and preferred information sources. (1976) (42)
THE HALCION STORY: TRIAL BY MEDIA (1980) (42)
Combined Clinical and Metabolic Study of the Effects of Alpha‐Methyldopa on Hypertensive Patients (1966) (41)
Biopharmaceuticals and Conventional Drugs: Clinical Success Rates (1992) (40)
Free‐living volunteer's motivations and attitudes toward pharmacologic studies in man (1977) (40)
Analgesic efficacy of an orally administered combination of pentazocine and aspirin; With observations on the use and statistical efficiency of GLOBAL subjective efficacy ratings (1977) (40)
The Role of the Research‐Based Pharmaceutical Industry in Medical Progress in the United States (1993) (39)
Research and Development Costs for New Drugs by Therapeutic Category (1995) (39)
The role of benzodiazepines in nonpsychiatric medical practice. (1977) (39)
The psychophysics of clinical pain. (1962) (39)
A comparison of hypnotic agents. (1954) (38)
How reliable are enteric‐coated aspirin preparations? (1965) (38)
PHENFORMIN AND LACTIC ACIDOSIS (1966) (37)
The analgesic effectiveness of codeine and meperidine (demerol). (1954) (36)
L-3,4-dihydroxyphenylalanine metabolism by the gut in vitro. (1971) (34)
Evaluation of current clinical trial methodology in analgesimetry based on experts' opinions and analysis of several analgesic studies (1983) (34)
Detoxication mechanisms. The metabolism and detoxication of drugs, toxic substances and other organic compounds (1961) (34)
Correlates of physicians' prescribing behavior. (1972) (34)
The placebo effect. (1986) (34)
Trends in Drug Development: The 1985‐86 New Drug Approvals (1987) (34)
Diuretics vs α-Blockers for Treatment of Hypertension: Lessons From ALLHAT (2000) (33)
Arcus not so senilis. (1968) (33)
The hypnotic efficacy of doxylamine (1967) (32)
Controversies in Therapeutics (1980) (32)
The effect of dosage regimen on the diuretic efficacy of chlorothiazide in human subjects. (1961) (32)
Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry. (1995) (30)
Characteristics and attitudes of physicians associated with the prescribing of chloramphenicol. (1971) (29)
ANALGESIC EFFICACY OF PARENTERAL METKEPHAMID ACETATE IN TREATMENT OF POSTOPERATIVE PAIN (1982) (29)
A comparative study of five proprietary analgesic compounds. (1962) (28)
DISCUSSION: PART III (1961) (28)
Investigating placebo effects in irritable bowel syndrome: a novel research design. (2006) (27)
A comparison of acetophenetidin and acetaminophen. II. Subjective effects in healthy volunteers. (1967) (27)
A doubleblind comparison of placebo and imipramine in the treatment of depressed patients in a state hospital. (1961) (26)
A plea for the “naturalistic” study of medicines (2004) (26)
Demystifying central review boards: current options and future directions. (2000) (26)
Discovering adverse drug reactions. (1983) (26)
The normal volunteer in clinical investigation: How rigid should selection criteria be? (1975) (26)
Interstitial gastric emphysema following gastroscopy; its relation to the syndrome of pneumoperitoneum and generalized emphysema with no evident perforation. (1951) (26)
Newer techniques and some problems in cooperative group studies. (1960) (25)
How Useful Are Serum Digitalis Measurements (1976) (25)
The New Drug Approvals of 1987, 1988, and 1989: Trends in Drug Development (1991) (24)
The Helsinki Declaration: timeless guide or irrelevant anachronism? (1995) (24)
Sounding Boards. Historical controls: the practitioner's clinical trials. (1982) (24)
Analgesic activity of oral naproxen in patients with postoperative pain. (1973) (24)
Patient package inserts. II. Toward a rational patient package insert (1975) (22)
Clinical pharmacology: present status and future development. (1966) (22)
The relation of psychiatry to pharmacology (1958) (22)
REDUCTION OF ANXIETY AND POSTOPERATIVE ANALGESIC REQUIREMENTS BY AUDIOVISUAL INSTRUCTION (1983) (21)
Placebos and controlled trials under attack (1979) (21)
Pharmacology in Medicine (1955) (20)
Thalidomide--a new nonbarbiturate sleep--inducing drug. (1960) (20)
Drug Development Process (1996) (20)
EVALUATING ADVERSE DRUG REACTIONS (1976) (20)
Attitudes of patients, housestaff, and nurses toward postoperative analgesic care Anesth. Analg., 4 (1983) 62–70 (1983) (19)
Attitudes toward appetite suppressants. A survey of US physicians. (1973) (19)
Fault and default. (1973) (18)
Murder most foul. (1982) (18)
The persistence of mental impairment following a hypnotic dose of a barbiturate. (1953) (18)
Report of a workshop on fixed-ratio drug combinations (1975) (18)
Diuretics vs alpha-blockers for treatment of hypertension: lessons from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. (2000) (18)
Relationship of Serum and Myocardial Digoxin Concentration to Electrocardiographic Estimation of Digoxin Intoxication (1978) (18)
Effects of aggregation and temperature on amphetamine toxicity in mice (1960) (17)
A comparison of drug product information in four national compendia (1983) (17)
Heroin: a medical "me too". (1981) (17)
Over-the-counter hypnotics and chronic insomnia in the elderly. (1995) (16)
The pharmaceutical revolution: its impact on science and society. (1969) (16)
Pharmaceutical regulation in the European Community: barriers to single market integration. (1992) (16)
Drug regulation in the United States and the United Kingdom: the Depo-Provera story. (1987) (16)
METHOTRIMEPRAZINE IN THE TREATMENT OF LABOR PAIN. (1964) (16)
Clinical evaluation of drugs. (1958) (16)
Drug effects as modified by aging. (1956) (16)
Nalorphine (n-allylnormorphine); practical and theoretical considerations. (1954) (16)
New drug development during and after a period of regulatory change: Clinical research activity of major united states pharmacxeutical firms, 1958 to 1979 (1983) (16)
Toxicity after large doses of noscapine. (1961) (16)
Combination drugs: Their use and regulation (1975) (16)
Clinical trials and tribulations. (1974) (16)
A comparison of acetophenetidin and acetaminophen. I. Analgesic effects in postpartum patients. (1967) (15)
The response of normal men to lysergic acid derivatives (di- and monoethyl amides); correlation of personality and drug reactions. (1956) (15)
Correlation between plasma concentrations of chlorpromazine and clinical response. (1978) (15)
An evaluation of hypnotic drugs in psychiatric patients. (1956) (14)
Some ethical problems in clinical investigation. (1968) (14)
A comparison of the effects of orally administered barbiturate salts and barbiturate acids on human psychomotor performance. (1968) (14)
[Sedatives and hypnotics]. (1959) (14)
An Analysis of Regulatory Review Times of Supplemental Indications for Already-Approved Drugs: 1989-1994 (1996) (13)
A study of hospital staff attitudes concerning the comparative merits of antibiotics (1971) (13)
Effects of SU‐13437 on serum lipids in hyperlipoproteinemic patients (1970) (13)
Current medical practice and the Food and Drug Administration. Some evidence for the existing gap. (1974) (13)
New drug applications: How long to gain approval? (1985) (13)
On reducing waste in foreign clinical trials and postregulation experience (1986) (13)
Low plasma levels of CPZ in patients chronically treated with neuroleptics. (1978) (12)
The development and regulation of new medications. (1978) (12)
Research regulation, and development of new pharmaceuticals: past, present, and future Part I (1972) (12)
Bias in the elucidation of subjective side-effects. (1981) (12)
More than skin deep: transdermal drug-delivery systems. (1986) (12)
A CONTROLLED CLINICAL EVALUATION OF TWO NEW ANALGESICS, PHENAZOCINE AND PHENAMPROMID (1960) (12)
The impact of regulations, tradition, and experimental design on clinical cancer trials: report and recommendations resulting from Washington Cancer Trials Conference. (1996) (11)
Prescription prices under the New York generic substitution law. (1980) (11)
A comparative evaluation of the hypnotic potency of chloral hydrate and trichloroethanol. I. Studies at the Johns Hopkins University School of Medicine. II. Studies at the St. Louis University School of Medicine. III. Studies at Harvard Medical School. (1955) (11)
New indications for already‐approved drugs: Time trends for the new drug application review phase (1987) (11)
Oral contraceptive patient information. (1976) (11)
Conjoint clinic on pain and analgesia. (1966) (11)
Clinical testing of products prepared by biotechnology. (1986) (11)
Are drug benefits also part of pharmacoepidemiology? (1990) (10)
Mebutamate as a hypnotic: Clinical trial and statistical considerations (1973) (10)
Clinical Pharmacology: Past, Present and Future (1983) (10)
Anorectic Drugs: Drug Policy Making at the State Level (1988) (10)
The Dose—Response Model for Dioxin (1998) (9)
Drug discovery and introduction: Regulation and overregulation (1976) (9)
The antidiuretic action of epinephrine and norepinephrine. (1952) (9)
New Indications for Already‐Approved Drugs: An Analysis of Regulatory Review Times (1991) (9)
From DNA to NDA--the impact of recombinant DNA technology on new drug development. (1985) (9)
PROBLEMS OF DRUG DEVELOPMENT. THE GOVERNMENT, THE DRUG INDUSTRY, THE UNIVERSITIES, AND THE MEDICAL PROFESSION: PARTNERS OR ENEMIES? (1964) (9)
Effect of naloxone on the analgesic activity of methadone in a 1:10 oral combination; Time and cost of flirting with the null hypothesis in tests of equivalence (1974) (9)
Metabolism of SU‐13437‐a new hypolipidemic drug in man (1970) (9)
Clinical trials in the natural environment (1985) (9)
A clinical trial of dextromoramide, (R 875, SKF D-5137). (1958) (9)
The analgesic potency of piminodine (alvodine). (1960) (8)
Toxicity of hepatotoxic drugs on mouse liver tissue culture. (1970) (8)
Balancing risks versus benefits in drug therapy decisions. (1998) (8)
A duty to die? (1984) (8)
Phenylpropanolamine and blood pressure. (1985) (8)
DRUG TOXICITY IN MAN: THE PROBLEM AND THE CHALLENGE (1965) (8)
The economics of generic prescribing: winners and losers. (1986) (8)
The safety and efficacy of the estrogen patient package insert. A questionnaire study. (1979) (8)
Initiatives to Speed New Drug Development and Regulatory Review: The Impact of FDA‐Sponsor Conferences (1996) (8)
Roots of scientific thought. A cultural perspective (1958) (8)
Digoxin-prescribing. Mostly good news. (1979) (8)
The FDA, Politics, and the Public (1975) (8)
A Survey of Therapeutic Substitution Programs in Ten Boston Area Hospitals (1992) (8)
Methodology for demonstrating sustained efficacy of hypnotics: A comparative study of triazolam and flurazepam (1979) (8)
Prisoner subjects and drug testing. (1977) (7)
The diseases and drug needs of the Third World. (1979) (7)
Availability of anticancer drugs in the United States, Europe, and Japan from 1960 through 1991 (1995) (7)
International Differences in Drug Regulation Philosophy (1986) (7)
Drugs Five Years Later: Propoxyphene Napsylate (1976) (7)
A controlled trial on chlorpromazine and promazine in the management of delirium tremens. (1958) (7)
Detection of Norepinephrine in the Parotid Gland Secretion of Bufo agua.∗ (1951) (7)
Tolerance to drug-induced writhing in mice. (1968) (7)
Pharmacokinetics of meperidine in man (1976) (7)
Clinical trials of drugs from the viewpoint of the academic investigator (a satire) (1975) (7)
Gripesmanship: a positive approach. (1959) (7)
Marihuana, The Forbidden Medicine: Revised and Expanded Edition. (1998) (7)
Herbal pharmacology and medical therapy in the People's Republic of China. (1975) (7)
CONCEPTS OF MEDICINE (1961) (7)
The pharmacological basis for the effective use of hypnotics. (1967) (6)
Controlled Trials: Nuisance or Necessity? (1962) (6)
A training program in clinical pharmacology. (1959) (6)
PROBLEMS OF DRUG DEVELOPMENT (1965) (6)
Graphical analysis of multivariate pain data in analgesic trials. (1986) (6)
Will all new drugs become orphans? (1982) (6)
PREDICTING HUMAN DRUG SAFETY FROM ANIMAL STUDIES : CURRENT ISSUES (1987) (6)
Feeling Good and Doing Better: Ethics and Nontherapeutic Drug Use (1985) (6)
DRUG EVALUATION PROBLEMS IN ACADEMIC AND OTHER CONTEXTS (1970) (6)
DEATH IN THE RING (1983) (5)
The relative importance of blood and urinary concentrations of sulfonamide in the treatment of urinary tract infections; a comparison of sulfisoxazole (gantrisin) and sulfamethoxypyridazine (kynex, midicel) in man and rat. (1958) (5)
Margin of safety. The story of poliomyelitis vaccine (1963) (5)
Graduated reciprocation in tension-reduction. A key to initiative in Foreign policy (1961) (5)
Across-the-counter hypnotics: boon, hazard, or fraud? (1956) (5)
The impact of scientific models on clinical psychopharmacology: a pharmacologist's view. (1972) (5)
The powerful cipher. (1980) (5)
Patient Perceptions of Drug Risks and Benefits (1990) (5)
The Response of Normal Men to Lysergic Acid Derivatives (Di-And Mono-Ethyl (1956) (5)
An introduction to the study of experimental medicine (1958) (5)
THE CLINICAL PHARMACOLOGY OF ANALGESICS AND ANALGESIC ANTAGONISTS (1968) (5)
Life, death, and the doctor (1968) (5)
Introduction and opening remarks (1972) (5)
The newer hypnotics. (1957) (5)
A White Paper on the Appropriateness of Proposals by the FDA to Modify Labeling of Benzodiazepine Sedative‐Hypnotics (1994) (4)
Illness Care???A Finite System? (1986) (4)
The Lilly Prize lecture. University of London, December 1986. On assuring pharmacotherapeutic progress in the 21st century. (1987) (4)
Randomized clinical trials. (1976) (4)
The price of prestige. (1985) (4)
A controlled study of chlorothiazide as a diuretic agent; with a note on untoward reactions in the presence of renal insufficiency. (1959) (4)
The Future of Pharmaceuticals: The Changing Environment for New Drugs (1981) (4)
Reflections in a crystal ball (1975) (4)
The future of clinical pharmacology. (1969) (4)
Oral ciramadol in the treatment of postoperative pain (1985) (4)
The clinical pharmacologist as a servant of society. (1967) (4)
Morphologic and biochemical changes in the gut after chronic treatment with L-dopa. (1973) (4)
A YEAR BOOK OF DRUG THERAPY (1952) (4)
A history of medicine. volume II: Early Greek, Hindu and Persian medicine: Henry E. Sigerist. Oxford University Press, New York, 1961. Pp. 352, indexed. Price $11.00 (1962) (4)
THE INVESTIGATOR'S RESPONSIBILITY TO THE PATIENT. (1963) (4)
DEVELOPMENT OF SUPPLEMENTAL INDICATIONS FOR ALREADY-APPROVED DRUGS BY THE UNITED STATES PHARMACEUTICAL INDUSTRY (1991) (4)
The Biological Revolution: Commercialization of the Molecule. (1987) (4)
Estrogen patient package insert: Medication acceptance despite negative attitudes (1981) (4)
Statistical uncertainty. (2002) (4)
Toxicological barriers to providing better drugs (1979) (4)
The drug industry and American medicine. (1958) (4)
Generic Drugs and the Elderly (1983) (4)
Lysosomal changes in the gut of rats after chronic treatment with phenobarbital. (1975) (3)
Report of the subcommittee on position and status of the clinical pharmacologist in drug research (1964) (3)
EFFICACY AND GENERIC DRUGS (1987) (3)
Effects of Potassium on the Guinea Pig after Barbiturate Administration (1952) (3)
Pharmacology in medicine. A collaborative textbook (1958) (3)
CURRENT STATUS OF INTERNATIONAL DRUG REGULATION (1978) (3)
The role of a division of clinical pharmacology in a university environment. (1961) (3)
The professional-patient dialogue. (1983) (3)
Clinical pharmacology in the United States: a personal reminiscence. (1985) (3)
The quantification of desired and undesired effects of reproductive controls; some principles and problems. (1965) (3)
The doctor and the dying patient. (1969) (3)
Obesity: causes, consequences, and treatment (1974) (3)
Problems Involved in the Study of Drug-Modified Behavior in Normal Humans. (1959) (3)
Generic substitution: trick or treat? (1978) (3)
Narcotic potency and side effects of anileridine and meperidine in man. (1958) (3)
The desire to regulate: the wish to discover. (1987) (3)
Under the Ether Dome (1983) (3)
Drug effects as modified by aging. (1956) (3)
Macrocyclic molecules and their pharmacological applications. (1993) (3)
The amphetamines. Their actions and uses (1959) (3)
Post-marketing surveillance. (1980) (3)
EXTRAPOLATION TO STUDIES IN MAN (1958) (3)
Over-the-counter niacin. (1994) (3)
Introductory statement on a symposium on pain and its relief. (1956) (3)
Benefit-risk ratio of agonist-antagonist analgesics. (1987) (3)
The New Drug Approvals of 1993, 1994, & 1995: Trends in Drug Development (1996) (3)
The World Health Organization list of "essential drugs.". (1980) (3)
Issues in pharmaceutical lotteries: The case of interferon beta‐1b (1997) (3)
Doctors dilemmas (1953) (3)
Effect of potassium and mag-nesium aspartates on athletic performance. (1963) (3)
Challenges in drug evaluation in man. (1970) (2)
Disease and the advancement of basic science (1961) (2)
Clinical investigation in medicine: Legal, ethical and moral aspects. An anthology and bibliography (1964) (2)
Knowledge of Drug Ingredients (1975) (2)
On the mechanism of the antidiuretic action of cinchoninic acid derivatives. (1952) (2)
Research regulation, and development of new pharmaceuticals: past, present, and future. 1. (1972) (2)
Commentary: the FDA, politics, and the public. (1975) (2)
One man's odd is another man's even. (1970) (2)
Toxicology: Mechanisms and analytical methods (1961) (2)
Drug Costs and Drug Quality (1974) (2)
Improving the Drug Development Process: Needed Reforms (1995) (2)
Clinical Judgment. Alvan R. Feinstein. Williams and Wilkins, Baltimore, 1967. 422 pp., illus. $9.50 (1967) (2)
Phase IV: the opportunity and the challenge (1988) (2)
Marijuana policy and drug mythology (1983) (2)
Reader's Guide: Cholesterol, Diet, Drugs and Death (1979) (2)
Fumifugium or, the inconvenience of the AER, and smoake of London dissipated (1965) (2)
Wanted: a new type of consumer advocate for drugs. (1978) (2)
The impact of regulations on the development of psychoactive drugs. (1979) (2)
Approvable Letters in the FDA New Drug Approval Process (1989) (2)
WOMEN AT RISK (1982) (2)
Analgesie activity of oral and intramuscular profadol (1971) (2)
Mortal decisions: What Kind of Life and Who Lives? Who Dies? (1991) (2)
Antidiuretic Effects of Physostigmine and Atropine in the Dog.∗ (1952) (2)
Wanted and unwanted drug effects: the need for perspective* (1979) (2)
Medical Foods: What is Sufficient Evidence to Support a Health-Medical Claim? (1997) (2)
Perioperative prophylaxis with cephalosporins (1984) (2)
Recent trends in drug development. (1997) (2)
How Much Regulation is Desirable in Industry (1983) (2)
Setting the scene — the role of regulation (1989) (2)
Caution on the pill. (1968) (2)
COMPARISON OF THE ANALGESIC POTENCY AND SIDE EFFECTS OF ANILERIDINE AND DEMEROL IN MAN (1957) (2)
On Achieving Consensus regarding Flexible Therapeutic End Points (1990) (1)
Calcium and CNS symptoms. (1969) (1)
Psychological Effects of Medication [Abridged] (1962) (1)
Statistics: A New Co-Carcinogen (1980) (1)
Drug Regulation Reform Act. (1979) (1)
Introduction: Aspirin's infinite variety (1983) (1)
Bioavailability and pharmacological effects of two slow-release theophylline preparations: intrasubject tablet-to-tablet variability. (1986) (1)
Clinical toxicology: The clinical diagnosis and treatment of poisoning. By S. Locket, M.B., B.S., M.R.C.P., (London), St. Louis, 1957, The C. V. Mosby Co. 772 pp., indexed. Price $20.00 (1958) (1)
Involuntary self-intoxication with triazolam. (1988) (1)
The liver and cancer: A new cancer theory (1961) (1)
Analgesic drugs. (1961) (1)
Absorption and distribution of drugs. Based on a symposium held by the Association of Medical Advisers in the Pharmaceutical Industry (1964) (1)
Statistics: vital and lively. (1966) (1)
Occlusion of the anterior spinal artery; a case report. (1949) (1)
Book Review The Powerful Placebo: From ancient priest to modern physician By Arthur K. Shapiro and Elaine Shapiro. 280 pp. Baltimore, Johns Hopkins University Press, 1997. $39.95. 0-8018-5569-1 (1998) (1)
THE ANALGESIC EFFICACY AND RESPIRATORY EFFECTS IN MAN OF A BENZOMORPHAN "NARCOTIC ANTAGNOST". (1964) (1)
Whitla's Dictionary of Medical Treatment (1957) (1)
Book Review:Vitamin C: Its Molecular Biology and Medical Potential. Sherry Lewin (1977) (1)
Drug concentrations in neuropsychiatry. Introduction: the rational use of plasma drug levels in clinical medicine. (2008) (1)
The adversary system and drug regulation. (1977) (1)
Letters to the EditorSOCIETY OVERMEDICATED (1974) (1)
Regulation and constraint of medical research: rights and human welfare. (1980) (1)
THE HALCION STORY (1980) (1)
Drugs through the ages. (1968) (1)
Hypnotic drugs. (2000) (1)
Propoxyphene napsylate. (1976) (1)
Pharmacogenetics. Heredity and the response to drugs: Werner Kalow, M.D. W. B. Saunders Co., Phila., 1962. 231 pp. Indexed. Price $8.00 (1963) (1)
The Ethical and Scientific Basis of Regulation (1980) (1)
Scientific and Political Components of Regulatory Decision Making: The United States Experience (1989) (1)
Masked Men of Science (1984) (1)
Why not a letters-to-the-editors section? (1963) (1)
A history of public health (1958) (1)
READER'S GUIDE: Legitimizing the Doctor's Bible (1980) (1)
Let Magic Cast Its Spell (1984) (1)
The Negative Power of Advertising (1980) (1)
Potential Effects on the Patient — 1 (1977) (1)
Towards a rapprochement between clinical pharmacology and behavioral pharmacology. (1981) (1)
READER'S GUIDE: Black and White (1981) (1)
Does the public need protection from itself? (1987) (1)
Minimum Acceptable Requirements for Introduction and Marketing of Drugs (2012) (1)
Planning clinical chemotherapy studies. (1960) (1)
Pain and its management. (1986) (1)
Discussion of ‘Do No Harm’ (1977) (1)
The Uncertain Future of Drug Development (1979) (1)
Reader's Guide: BE PREPARED (1981) (1)
The Management of Pain (2012) (1)
The Mind and Morality of the Doctor ** (1965) (1)
Update to "Over-the-counter hypnotics and chronic insomnia in the elderly" (guest editorial, J Clin Psychopharmacol 1995;15:383-6) (1996) (1)
Henry E. sigerist on the sociology of medicine (1960) (1)
The executioner's syringe. (1983) (1)
The relation of dosage schedule to the therapeutic efficacy of terramycin. (1952) (1)
Year book of drug therapy, 1959–1960 series: Edited by Harry Beckman, M.D. Chicago, 1959, Year Book Publishers, Inc. Pp. 656, indexed. Price $8.50 (1960) (1)
The Catastrophic Care Act: lessons to be learned. (1990) (1)
Correspondence from the University of Mississippi Medical Center (1965) (1)
No Place Like Home (1979) (1)
The mind and morality of the doctor. II. The physician and the macrocosm. 1965. (1965) (1)
Note to the paper “the influence of side-effects on the reporting of symptoms” by F. J. J. Letemendia and A. D. Harris (1960) (1)
The Therapist and the Researcher: Clinical Judgment . Alvan R. Feinstein. Williams and Wilkins, Baltimore, 1967. 422 pp., illus. $9.50. (1967) (0)
THE INVESTIGATOR'S RESPONSIBILITY TO THE PATIENT. (1963) (0)
Ethics and informed consent. (1987) (0)
Is narcotic addiction a chronic disease? (1966) (0)
TWENTIETH CENTURY THERAPEUTICS AND RIP VAN WINKLE. (1963) (0)
GRANT'S LAST STAND (1982) (0)
Book ReviewThe Healing Hand: Man and wound in the ancient world. (1976) (0)
Drug regulation. (1978) (0)
Letter: Abuse of amphetamines. (1974) (0)
PAIN AND PLACEBOS (1957) (0)
Morphine and allied drugs (1958) (0)
Analgesic compounds. (1963) (0)
GOING THE DISTANCE (1981) (0)
Antibiotics in medicine (1960) (0)
Correspondence (1961) (0)
Letter to the editor (1993) (0)
Today's drugs: Specially commissioned articles from the British Medical Journal. British Medical Association, London, 1964. 400 pp. Indexed. Price £1 10s (1966) (0)
Historical Viewpoint of Clinical Trials (1982) (0)
Regional neurochemistry. The regional chemistry, physiology and pharmacology of the nervous system: Proceedings of the Fourth International Neurochemical Symposium, June 1960: Edited by Seymour S. Kety and Joel Elkes. Pergamon Press, New York, 1961. Pp. 540, indexed. Price $12.00 (1962) (0)
The Use and Misuse of Sleeping Pills (1981) (0)
Are we an over-medicated society? (1982) (0)
READER'S GUIDE: The Sea Disease (1980) (0)
Drugs for pain. (1979) (0)
Chemobiodynamics and drug design (1961) (0)
The drug-reaction drama (1989) (0)
Principles of internal medicine (1958) (0)
Reader's Guide: The Writing on the Wall (1979) (0)
The pill and strokes. (1967) (0)
Actions of Barbiturate (1963) (0)
FDA 'efficacy' rule: does it work? (1971) (0)
Generic vs. brand name drugs--defining and enforcing standards. (1979) (0)
The antidiuretic activity of some organic acids. (1952) (0)
The FOURTH CHRIST OF YPSILANTI (1983) (0)
Book ReviewPsychotropic Drug Side Effects: Clinical and theoretical perspectives. (1971) (0)
An Affinity for Chemistry (1992) (0)
Book Review:Poisons of the Past: Molds, Epidemics, and History. Mary Kilbourne Matossian (1990) (0)
The torch: Wilder Penfield M.D. Boston, 1960, Little, Brown & Company. Pp. 370, indexed. Price $4.75 (1961) (0)
The complications of modern medical practices. A treatise on iatrogenic diseases (1964) (0)
Influence of age on analgesic pain relief. (1971) (0)
The problems of drug research and development. (1976) (0)
Preferences in antibiotic prescribing. (1971) (0)
Book ReviewModern Trends in Pharmacology and Therapeutics (1968) (0)
The Degradation of Grades (1980) (0)
An introduction to the study of disease (1962) (0)
Book reviewBedside medicine: I. Snapper, M.D. New York, 1960, Grune & Stratton, Inc. Pp. 592, indexed. Price $14.50 (1961) (0)
Concluding Remarks (2012) (0)
Drugs and behavior (1961) (0)
READER'S GUIDE: Alive and Not Well (1981) (0)
A Symposium on the Evaluation of Drug Toxicity. (1959) (0)
Advances in Drug Research. vol. 1. N. J. Harper and Alma B. Simmonds, Eds. Academic Press, New York, 1964. x + 209 pp. Illus. $6.25 (1964) (0)
Letter: Iron in bread. (1975) (0)
Neuropharmacology: Transactions of the fifth conference. May 27–29, 1959, Princeton, N.J. Edited by Harold A. Abramson, M.D. New York, 1960, Josiah Macy Jr. Foundation. Pp. 251, indexed. Price $6.00 (1961) (0)
A history of nutrition (1959) (0)
Books Received (1986) (0)
The misrepresentation of arthritis drugs and devices in the United States. A report to the committee on arthritis advertising, the arthritis and rheumatism foundation (1961) (0)
Non-specific Aspects of Treatment . Edited by M. Shepherd and N. Sartorius. (Pp. 149; $39.00.) Hans Huber: New York. 1989. (1990) (0)
Science and human values: J. Bronowski, Ph.D. London, 1961, Hutchinson & Co., Ltd. Pp. 96, unindexed, with notes. Price 12s, 6d (1961) (0)
Book ReviewPrescriptions for Death: The drugging of the third world (1982) (0)
Research on novocain therapy in old age. A collection of seven papers from die therapiewoche, 1956–1957 (1959) (0)
X-ray photographs of three flowers: morning glories (0)
Book ReviewSide Effects of Drugs Annual 2: A worldwide yearly survey of new data and trends. (1978) (0)
History of american medicine. A symposium (1959) (0)
Medicine as an art and a science: A. E. Clark-Kennedy, M.A., M.D. F.R.C.P. and C. W. Bartley, M.A. D.M., M.D., M.R.C.P. Lippincott, Philadelphia, 1960. pp. 425, indexed. price $6.25 (1962) (0)
Barriers to Effective Antiinfective Therapy: The Perspective of a Clinical Pharmacologist (1989) (0)
Reader's Guide: Ah, Sweet Mysteries of Life (1979) (0)
Contributions to the psychobiology of aging (1966) (0)
Advocacy: a new role for cancer patients. (1991) (0)
Hypnotic drugs. (1972) (0)
Windsor C. Cutting Memorial Lecture. Clinical pharmacology: hard sell or soft? (1976) (0)
Patient package inserts: goals versus achievements. (1982) (0)
Book Review Research Fraud in the Behavioral and Biomedical Sciences Edited by David J. Miller and Michel Hersen. 251 pp. New York, John Wiley, 1992. $30. ISBN 0–471–52068–3 . (1992) (0)
Elementary medical statistics (1964) (0)
Reader's Guide: Scientific Jet Set (1979) (0)
Need for Research Reviews: Advances in Drug Research . vol. 1. N. J. Harper and Alma B. Simmonds, Eds. Academic Press, New York, 1964. x + 209 pp. Illus. $6.25. (1964) (0)
Experiment perilous. Physicians and patients facing the unknown: Renée C. Fox. Glencoe, Ill., 1959, The Free Press. Pp. 262, index. Price $5.00 (1959) (0)
Dose-response relationships in clinical pharmacology : proceedings of the Esteve Foundation Symposium III, dose-response relationships in man, Son Vida, Mallorca, 13-15 October 1988 (1989) (0)
Centaur. Essays on the history of medical ideas (1959) (0)
REPORT OF WASHINGTON CONFERENCE ON THE DRUG REGULATION REFORM ACT OF 1978 (1979) (0)
Closing Comments (2012) (0)
Quantitative methods in pharmacology: Proceedings of a Symposium Held in Leyden, 10–13 May 1960. Edited by H. De Jonge. Interscience, New York, 1961. Pp. 391, Unindexed (1962) (0)
Psychotrophic drugs: Edited by S. Garattini and Z. Ghetti. Proceedings of the International Symposium on Psychotrophic Drugs, Milan, May 9–11, 1957. New York, 1957, Elsevier Publishing Company. Distributed by D. Van Nostrand Company, Inc. 606 pp., indexed. Price $19.50 (1958) (0)
Statistics. A new approach: W. Allen Wallis and Harry V. Roberts. Glencoe, 1956, The Free Press. Pp. 646, indexed. Price $7.00 (1961) (0)
Book reviewThe new Year Book of Drug Therapy: 1960–1961 Series. Edited by Harry Beckman, M.D. Chicago, 1961, The Year Book Publishers, Inc. Pp. 587, indexed. Price $8.50 (1961) (0)
Defining Our Future Work (2012) (0)
Editorial: Drug costs and drug quality. (1974) (0)
Use and abuse of statistics: W. J. Reichmann. Oxford University Press, New York, 1962. 336 pp. Indexed. Price $5.00 (1964) (0)
Drug therapy: Frank C. Ferguson, Jr. Lea & Febiger, Philadelphia, 1962. 411 pp. Indexed. Price $7.50 (1963) (0)
Cardiovascular abstracts I-1960 (1961) (0)
ONE-A-DAY. PLUS C (1981) (0)
The Heartbreak of Pharmaceutical Failure (2002) (0)
A short history of the gout and the rheumatic diseases , University of California Press, 1964. 236 pp. Indexed. Price $6.00 (1965) (0)
Pain: Robert S. Knighton, M.D. and Paul R. Dumke, M.D., Editors. Little, Brown and Company, 1966. 587 pp. Indexed. $17.50 (1967) (0)
Rmde's Guide (1982) (0)
Cost and Price of Comparable Branded and Generic Pharmaceuticals-Reply (1987) (0)
The dynamics of anxiety and hysteria: By J. J. Eysenck, Ph.D. New York, 1957, Frederick A. Praeger. Pp. 311, indexed. Price $5.00 (1958) (0)
DISCUSSION: PART V (1961) (0)
“Mickey Finn” (1963) (0)
Scientific writing: Meta Riley Emberger and Marian Ross Hall. New York, 1955, Harcourt, Brace and Company. Pp. 468, indexed. Price $4.50 (1958) (0)
Concluding Remarks (2012) (0)
William Harvey. His life and times: His discoveries: His methods (1958) (0)
Annals of epidemiology: Berton Roueche. Little, Brown and Co., Boston, 1967. 307 pp. Indexed. Price $7.00 cloth, $4.00 paper (1967) (0)
The year book of medicine, 1962–1963 series Edited by , , , , and . Year Book Medical Publishers, Chicago, 1962. 735 pp. Indexed. Price $8.00 (1963) (0)
Book Review:Vitamin C, the Common Cold, and the Flu. Linus Pauling (1977) (0)
Defining our Future Work (2012) (0)
Book ReviewThe Principles and Practice of Clinical Trials: Based on a symposium organised by the Association of Medical Advisers in the pharmaceutical industry. (1971) (0)
Letters: Rejoinder. (1975) (0)
Experimental pharmacodynamics: T. Koppanyi and A. G. Karczmar. Minneapolis, 1955, Burgess Publishing Co. Pp. 256. Price $5.00 (1958) (0)
AN IMPATIENT PRESS (1983) (0)
The dreams of reason. Science and utopias: René Dubos. Columbia University Press, New York, 1961. pp. 167, unindexed. price $5.00 (1962) (0)
The child with mongolism: Clemens E. Benda, M.D. Grune & Stratton, New York, 1960. 276 pp. Indexed. Price $9.50 (1963) (0)
Observations on Krebiozen in the management of cancer (1957) (0)
Effecting euthanasia should not be secretive. (1973) (0)
Psychopharmacology frontiers: Edited by Nathan S. Kline, M.D. Boston, 1959, Little, Brown & Co. Pp. 533, unindexed. Price $10.00 (1960) (0)
Drugs for pain. (1979) (0)
The year book of medicine (1963–1964 series) (1964) (0)
Evaluation of drug therapy. Proceedings of the symposium on evaluation of drug therapy in neurologic and sensory diseases held at the University of Wisconsin, May, 1960 (1961) (0)
Book Review:Man and His Future. Ciba Foundation Volume. Gordon Wolstenholme (1965) (0)
BOOKS: Transnational Firms vs. Developing Countries (1984) (0)
READER'S GUIDE: Dear Hearts (1980) (0)
The physician-writer's book. Tricks of the trade of medical writing (1958) (0)
Issues Facing the New FDA Commissioner (1998) (0)
Iron in Bread (1975) (0)
Counseling the dying: Margaretta K. Bowers, Edgar N. Jackson, James A. Knight and Lawrence Leshan. Thos. Nelson & Sons, New York, 1964. 183 pp. Not indexed. $4.50 (1965) (0)
Sponsored meetings and publications: a round-table discussion (1988) (0)
Hallucinogenic drugs: F. Christine Brown. Springfield: Charles C. Thomas, 1972. 147 pp. indexed. $10.50 (1973) (0)
Chemical Coping: A Report on Legal Drug Use in the United States.Carl D. Chambers , James A. Inciardi , Harvey A. Siegal (1976) (0)
PELVIC EXAMS EXAMINED (1981) (0)
[Clinical pharmacology in USA and Western Countries (author's transl)]. (1980) (0)
The journal changes editors (1965) (0)
Drugs, medicines and man (1962) (0)
READER'S GUIDE: Private Universities and the Public Weal (1981) (0)
Commentary. Reflections in a crystal ball. (1975) (0)
READER'S GUIDE: There Goes the Judge (1981) (0)
Klinik und therapie der vergiftungen: Sven Moeschlin. Pp. 521. Indexed. Stugart, Gemmany, 1955. George Thieme Verlag. (In the U. S. A. and Canada, The Intercontinental Medical Book Corporation, New York, N. Y.), Price $14.05 (1956) (0)
Readings in pharmacology (1965) (0)
Constraints on innovation in drug development and use. (1972) (0)
Preferences in antibiotic prescribing. (1971) (0)
A bibliography of internal medicine. Selected diseases (1960) (0)
International co‐operation in drug testing [letter]. (1976) (0)
Editorial: How useful are serum digitalis measurements? (1976) (0)
Molecules and mental health (1960) (0)
The year book of drug therapy (1961–1962 series): Edited by Harry Beckman. Year Book Medical Publishers, Chicago, 1961. Pp. 597, indexed. Price $8.50 (1962) (0)
International co-operation in drug testing (1976) (0)
READER'S GUIDE: The Greening of an Emeritus (1981) (0)
Analgesics in the 1980s. (1985) (0)
Relief of Symptoms (1962) (0)
Henry E. Sigerist on the history of medicine: Edited and with an introduction by Felix Marti-Ibañez, M.D. Foreword by John F. Fulton, M.D. New York, 1960, M.D. Publications, Inc. Pp. 313, indexed. Price $6.75 (1960) (0)
The Future of Pharmaceutical Therapy and Regulation (1994) (0)
Illustrated manual of neurologic diagnosis (1962) (0)
Regulated research. (1979) (0)
Principles of research in biology and medicine (1958) (0)
A history of ophthalmology (1959) (0)
Goodman and Gilman's the Pharmacological Basis of Therapeutics (1986) (0)
Biology of pyelonephritis: Edited by Edward L. Quinn, M.D., F.A.C.P. and Edward H. Kass, M.D., Ph.D., M.A. (hon.), F.A.C.P. Boston, 1960, Little, Brown & Company. Pp. 708, indexed. Price $18.00 (1961) (0)
Letter: Review of "VD Epidemic". (1975) (0)
Summation of meeting (1972) (0)
VA prospectus: Research in aging (1959) (0)
The role and responsibility of industry in research. (1987) (0)
A history of neurology (1959) (0)
Negroes and medicine (1958) (0)
TEXTBOOK OF MEDICAL TREATMENT (1946) (0)
Reader's Guide: Fortified Booze (1979) (0)
Letter: Knowledge of drug ingredients. (1975) (0)
The pharmacological basis of therapeutics (1955) (0)
Symposium on coronary heart disease: Edited by Herrman L. Blumgart, M.D. New York, 1961, The American Heart Association. Pp. 154, indexed (1961) (0)
Follow-up statements onmarijuana policy and drug mythology (1983) (0)
A matter of perspective. (1962) (0)
The history of the therapy of tuberculosis and the case of Frederick Chopin (1956) (0)
Response : Drug Regulation (1978) (0)
Introduction to “exploratory trials with anticancer agents in man” (1962) (0)
With a Wing and a Prayer (1985) (0)
Setting the record straight on “To the fullest extent” (1968) (0)
Ethics of post-hepatitis exercise. (1970) (0)
Medac medical advisory council series innovation and acceleration in clinical drug development (1987) (0)
Laennec: His life and times (1961) (0)
The medical center, the patient and the clinician. (1963) (0)
Drugs and the mind (1958) (0)
1963-1964 Year Book of Drug Therapy. (1964) (0)
Reports on past meetings (1982) (0)
Ciba Foundation Symposium on the cerebrospinal fluid, production, circulation and absorption (1958) (0)
Letter: Medical advisers in the pharmaceutical industry. (1976) (0)
The Doctor and the Dying Patient (1994) (0)
Man's worst enemy: Himself (1964) (0)
The year book of medicine (1959) (0)
Presentation of the Louis Lasagna Chair of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine (1998) (0)
Advances in pharmacology. Vol. 1: Edited by Silvio Garattini and Parkhurst A. Shore. Academic Press, Inc., New York, 1962. 474 pp. Indexed. Price $13.00 (1963) (0)
Book reviewPhysical diagnosis: F. Denette Adams, M.D. Ed. 14. Baltimore, 1958, Williams & Wilkins Co. Pp. 926, indexed. Price $12.00 (1958) (0)
Hormones in blood (1958) (0)
Enzymes and drug action: Edited by J. L. Mongar, Ph.D. and A. V. S. de Reuck M.Sc., D.I.C. Little, Brown & Co., Boston, 1962. 556 pp. Indexed. Price $12.50 (1963) (0)
The press: A. J. Liebling. Ballantine Books, New York, 1961. Pp. 284, not indexed. Price 75¢ (1962) (0)
The historical development of British psychiatry. Volume I: 18th and 19th Century: Denis Leigh. Pergamon Press, Oxford, 1961. Pp. 277, indexed. Price $10.00 (1962) (0)
CLINICAL USEFULNESS OF SERUM-DIGOXIN (1976) (0)
Book Review:Advances in Pharmacology. Volume 2. Silvio Garattini, Parkhurst A. Shore (1964) (0)
Training in clinical pharmacology (1973) (0)
Review of VD Epidemic (1975) (0)
Book reviewMirage of health: René Dubos. World Perspectives, Vol. XXII. New York, 1959, Harper and Brothers. Pp. 236, unindexed. Price $4.00 (1959) (0)
READER'S GUIDE: Sleep and the Golden Mean (1980) (0)
International co-operation in drug testing. (1976) (0)
Evening Reflections (1998) (0)
Medieval and renaissance medicine (1960) (0)
Academic Scientists and the Pharmaceutical Induṡtry: Cooperative Research in Twentieth-Century America (1988) (0)
The story of dissection (1960) (0)
Aphrodisiacs: From legend to prescription: By Alan Hull Walton. Westport, Conn., 1958, Associated Booksellers. Pp. 267, indexed. Price $7.95 (1959) (0)
Society and Medication: Conflicting Signals for Prescribers and Patients (1983) (0)
The year book of medicine, 1959–1960 series (1960) (0)
Chemotherapy and the central nervous system (1959) (0)
Academy marijuana report. (1982) (0)
Book ReviewToxicology: The basic science of poisons. (1976) (0)
Innovation and acceleration in clinical drug development : Merck Sharp & Dohme International Medical Advisory Council, Siena, Italy, June 9-10, 1986 (1986) (0)
Book Review:Dimensions in Health Research: Search for the Medicines of Tomorrow. Herbert Weissbach, Robert M. Kunz (1979) (0)
The Mind and Morality of the Doctor ** (1965) (0)
Over-the-counter analgesics: rational developments in the future. (1988) (0)
EditorialA new series of teaching clinics (1964) (0)
The preservation of youth. Essays on health: Moses Ben Maimon (Maimonides). Translated from the original Arabic (Fi Tadbir as-Sihha). With an introduction by Hirsch L. Gordon, M.D., Ph.D., D.H.L. New York, 1958, Philosophical Library, Inc. Pp. 92. Price $2.75 (1958) (0)
Book Review:Psychopharmacology Frontiers. Proceedings of the Psychopharmacology Symposium of the Second International Congress of Psychiatry Held in Zurich, Switzerland, on September 2-4, 1957. Nathan S. Kline (1961) (0)
In Pursuit of Profitability and Effectiveness in the Global Pharmaceutical Industry: Comments on Professor Walker's Four Challenges (1997) (0)
Unwilling patients. (1981) (0)

This paper list is powered by the following services:

Other Resources About Louis Lasagna

en.wikipedia.org

What Schools Are Affiliated With Louis Lasagna?

Louis Lasagna is affiliated with the following schools:

Louis Lasagna's Academic­Influence.com Rankings

Why Is Louis Lasagna Influential?

Louis Lasagna's Published Works

Published Works

Other Resources About Louis Lasagna

What Schools Are Affiliated With Louis Lasagna?

Image Attributions

Louis Lasagna's AcademicInfluence.com Rankings